Preview

Артериальная гипертензия

Расширенный поиск

ВИТАМИН D, ОЖИРЕНИЕ И РИСК КАРДИОРЕНАЛЬНЫХ НАРУШЕНИЙ У ДЕТЕЙ

https://doi.org/10.18705/1607-419X-2015-21-1-48-58

Полный текст:

Аннотация

В обзоре рассмотрены некоторые механизмы плейотропного действия витамина D, значимости уровня 25 (ОН)D в плазме как индикатора обеспеченности организма витамином, вопрос о токсичности витамина D. Отражены современные представления о строении и функциях витамин D-рецептора, регуляции экспрессии витамин D-зависимых генов. Обсуждается адипогенная активность витамина D, роль его метаболитов, витамин D-связывающего протеина, фактора роста фибробластов-23 в регуляции жирового, углеводного и энергетического обмена. Приводятся данные экспериментальных и клинических исследований влияния дефицита витамина D на развитие инсулинорезистентности, сердечно-сосудистых заболеваний и патологии почек. Показаны перспективы клинического применения витамина D в ренопротекции, влияния на ренин-ангиотензиновую систему, модификации эффектов гена, ассоциированного с ожирением (FTO) у детей. Требуются дальнейшие исследования для выработки практических рекомендаций по применению витамина D при ожирении и метаболическом синдроме у детей.

Об авторах

Н. Б. Куприенко
Северо-Западный федеральный медицинский исследовательский центр, Санкт-Петербург Первый Санкт- Петербургский государственный медицинский университет имени академика И. П. Павлова
Россия
Куприенко Наталья Борисовна — кандидат медицинских наук, доцентмладший научный сотрудник научно-исследовательской лабо- ратории диагностики и лечения патологии детского возраста Института перинатологии и педиатрии ФГБУ «СЗФМИЦ» Минздрава России, доцент кафедры педиатрии ГБОУ ВПО ПСПбГМУ им. И. П. Павлова Минздрава России


Н. Н. Смирнова
Северо-Западный федеральный медицинский исследовательский центр, Санкт-Петербург Первый Санкт- Петербургский государственный медицинский университет имени академика И. П. Павлова
Россия
Смирнова Наталия Николаевна — доктор медицинских наук, профессор, старший научный сотрудник научно-исследовательской лаборатории диагностики и лечения патологии детского возраста Института перинатологии и педиатрии ФГБУ «СЗФМИЦ» Минздра- ва России, заведующая кафедрой педиатрии ГБОУ ВПО ПСПбГМУ им. И.П. Павлова Минздрава России


Список литературы

1. Lai YH, Fang TC. The pleiotropic effect of vitamin D. I S R N N e p h r o l o g y. 2 0 1 3 ; 2 0 1 3 : A r t i c l e I D 8 9 8 1 2 5 . 6 p . doi:10.5402/2013/898125.

2. Welles CC, Whooley MA, Karumanchi SA et al. Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the heart and soul study. Am J Epidemiol. 2014;179(11):1279–1287. doi: 10.1093/aje/kwu059.

3. Каронова Т. Л. Мет аболиче ские и молекулярногенетические аспекты обмена витамина D и риск сердечнососудистых заболеваний у женщин: автореферат дис. … д-ра мед. наук: 14.01.05, 14.01.02. Первый Санкт-Петербург. гос. мед. ун-т им. акад. И. П. Павлова. СПб; 2014:34 с.: ил., табл. — Библиогр.: с. 26–33(57 назв.). [Karonova TL. Metabolic and molecular genetic aspects of the metabolism of vitamin D and risk of cardiovascular disease in women abstract dis. …Dr. med. Sciences: 14.01.05, 14.01.02. First Pavlov State Medical University of St Petersburg. SPb; 2014:34 p.: ill., table. — Bibliogr.: S. 26–33 (57 titles). In Russian].

4. Ивашкина Т. М., Котова Т. Н., Хлехлина Ю. В., Ермаков А. И., Берестовская В. С. Выявление дефицита витамина D3 у дошкольников и школьников Москвы и Санкт-Петербурга. Клин. лаб. диагно стика. 2011;11:22–24. [Ivashkina TM, Kotova TN, Khlekhlina JV, Ermakov A, Berestovskaya VS. Identification of deficiency of vitamin D3 in preschool children and schoolchildren in Moscow and St. Petersburg. Klin Lab Diagnostics. 2011;11:22–24. In Russian].

5. Glenville J, Prosser DE. The activating enzymes of vitamin D metabolism (25 and 1α-Hydroxylases). Academic Press. 2011;3:23–42.

6. Van Driel M., Koedam M, Buurman CJ, Hewison M, Chiba H, Uitterlinden AG. Evidence for auto/paracrine actions of Vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J. 2006;20(13):2417–2419.

7. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007;18 (6):1637–1647.

8. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19 (3):429–435.

9. Razzaque MS. Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol. Dial. Transplant. 2009;24 (1):4–7.

10. Krajisnik T, Björklund P, Marsell R, Ljunggren O, Akerström G, Jonsson KB et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007;195(1):125–131.

11. Lafage-Proust MN. Does the down regulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients? Kidney Int. 2010;77(5):390–392.

12. Zerwekh JE. Blood biomarkers of Vitamin D status. Am J Clin Nutr. 2008;87(4):1087S-1091S.

13. Braegger C, Campoy C, Colomb V, Decsi T, Domellof M, Fewtrell M et al. Vitamin D in the healthy European paediatric population: consensus statement. J Peadiatric Gastroenterol Nutr. 2013;56(6):692–701.

14. Ross AC, Taylor CL, Yaktine AL, Del Valle HB. Editors Dietary reference intakes for calcium and vitamin D / Institute of medicine (US) committee to review dietary reference intakes for vitamin D and calcium;. Washington (DC): National Academies Press (US); 2011. [Internet]. Avaiabe from: http://www.ncbi.nlm. nih.gov/books/NBK56070/(date of access — 26.10.2014).

15. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011;364(3):248–254. doi: 10.1056/NEJMcp1009570.

16. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel AV et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172(1):81–93. doi: 10.1093/aje/kwq120.

17. EFSA panel on dietetic products, nutrition and allergies (NDA). Scientific opinion on the tolerable upper intake level of vitamin D. EFSA J. 2012;10(7):2813 [45 pp.]. doi:10.2903/j. efsa.2012.2813.

18. Pinette KV, Yee YK, Amegadzie BY, Nagpal S. Vitamin D receptor as a drug discovery target. Mini Reviews in Medicinal Chemistry. 2003;3(3):193–204.

19. Barsony J, Pike JW, DeLuca HF, Marx SJ. Immunocytology with microwave-fixed fibroblasts shows 1 alpha, 25-dihydroxyvitamin D3 dependent rapid and estrogen-dependent slow reorganization of vitamin D receptors. J Cell Biol. 1990;111(6 Pt 1):2385–2395.

20. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010;20(10):1352–1360.

21. Nagpal S, Na S, Rathnachalam R. Non-calcemic action of vitamin D receptor ligands. Endocrine Reviews. 2005;26 (5):662–687.

22. Баннур Р., Войтович А. Н., Ларионова В. И. Роль рецептора к витамину D и его генетического полиморфизма в прогнозировании течения миопии у детей. Офтальмологические ведомости. 2010;3(3):27–33. [Bannur R, Wojtowicz AN, Larionova VI. Role of the vitamin D receptor and its genetic polymorphism in the prediction of the course of myopia in children. Ophthalmic statements. 2010;3(3):27–33. In Russian].

23. 3 . M a r t i n e a u A R , H o n e c k e r F U , Wi l k i n s o n R J , Griffiths CJ. Vitamin D in the treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol. 2007;103(3–5):793–798.

24. Gombart AF, Bhan I, Borregaard N, Tamez H, Camargo CA Jr, Koeffler HP et al. Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect. 2009;48(4):418–424.

25. Paula FJA, Rosen CJ. Bone remodeling and energy metabolism: new perspectives. Bone research. 2013;1(1):72–84. doi: 10.4248/BR201301005.

26. Khor GL, Chee WS, Shariff ZM, Poh BK, Arumugam M, Rahman JA et al. High prevalence of vitamin D insufficiency and its association with BMI-for-age among primary school children in Kuala Lumpur, Malaysia. BMC Public Health. 2011;11:95. doi: 10.1186/1471–2458–11–95.

27. Çizmecioğlu FM, Etiler N, Görmüş U, Hamzaoğlu O, Hatun Ş. Hypovitaminosis D in obese and overweight schoolchildren. J Clin Res Pediatr Endocrinol. 2008;1(2):89–96. doi: 10.4008/jcrpe. v1i2.43.

28. Каронова Т. Л., Гринева Е. Н., Михеева Е. П., Беляева О. Д., Красильникова Е. И., Никитина И. Л. Уровень витамина D и его взаимосвязь с количеством жировой ткани и содержанием адипоцитокинов у женщин репродуктивного возраста. Проблемы эндокринологии. 2012;58 (6):19–23. [Karonova TL, Grineva EN, Mikheeva EP, Belyaeva OD, Krasilnikova EI, Nikitina IL. Levels of vitamin D and its relationship with the amount of adipose tissue and the content of adipocytokines in women of reproductive age. Problemy Endokrinologii = The Problems of Endocrinology. 2012;58(6):19–23. In Russian].

29. Никитина И. Л., Тодиева А. М., Каронова Т. Л., Гринёва Е. Н. К вопросу о метаболических нарушениях у детей со сниженным уровнем витамина D и ожирением. Лечащий врач. 2014;3:10. [Nikitina I. L., Todiyeva A. M., Karonova T. L., Grineva E. N. To a question of metabolic violations at children with the reduced level of vitamin D and obesity. Attending Physician. 2014; 3:10. In Russian].

30. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690–693.

31. Reinehr T, de Sousa G, Alexy U, Kersting M, Andler W. Vitamin D status and parathyroid hormone in obese children before and after weight loss. Eur J Endocrinol. 2007;157(2):225–232.

32. Bellia A, Marinoni G, D’Adamo M, Guglielmi V, Lombardo M, Donadel G et al. Parathyroid hormone and insulin resistance in distinct phenotypes of severe obesity: a cross-sectional analysis in middle-aged men and premenopausal women. J Clin Endocrinol Metab. 2012;97(12):4724–4732.

33. Lind L, Hänni A, Lithell H, Hvarfner A, Sörensen OH, Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens. 1995;8(9):894–901.

34. Tai K, Need AG, Horowitz M, Chapman IM. Vitamin D, glucose, insulin, and insulin sensitivity. Nutrition. 2008;24 (3):279–285.

35. Muscogiuri G, Sorice GP, Prioletta A, Policola C, Della Casa S, Pontecorvi A et al. 25-hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. Obesity. 2010;18(10):1906–1910.

36. Bellan M, Guzzaloni G, Rinaldi M, Merlotti E, Ferrari C, Tagliaferri A et al. Altered glucose metabolism rather than naive type 2 diabetes mellitus (T2DM) is related to vitamin D status in severe obesity. Cardiovasc Diabetol. 2014;13(57). doi:10.1186/1475– 2840–13–57.

37. Karhapää P, Pihlajamäki J, Pörsti I, Kastarinen M, Mustonen J, Niemelä O et al. Diverse associations of 25-hydroxyvitamin D and 1,25-dihydroxy-vitamin D with dyslipidaemias. J Intern Med. 2010;268(6):604–610.

38. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the third national health and nutrition examination survey. Arch Intern Med. 2007;167(11):1159–1165.

39. Reis JP, von Muhlen D, Miller ER. Relation of 25-hydroxyvitamin D and parathyroid hormone levels with metabolic syndrome among US adults. Eur. J. Endocrinol. 2008;159(1):41–48.

40. Lee DM, Rutter MK, O’Neill TW, Boonen S, Vanderschueren D, Bouillon R et al. Vitamin D, parathyroid hormone and the metabolic syndrome in middle-aged and older European men. Eur J Endocrinol. 2009;161(6):947–954. doi:10.1530/EJE-09– 0496.

41. Røislien J, Van Calster B, Hjelmesæth J. Parathyroid hormone is a plausible mediator for the metabolic syndrome in the morbidly obese: a cross-sectional study. Cardiovasc Diabetol. 2011;10:17. doi: 10.1186/1475–2840–10–17.

42. Тодиева А. М., Никитина И. Л., Каронова Т. Л., Васильева Е. Ю., Буданова М. В. Витамин D и метаболический статус у детей и подростков с ожирением. Вопросы детской диетологии. 2013;11(3):15–21. [Todiyeva A. M., Nikitina I. L., Karonova T. L., Vasilieva EY, Budanova MV. Vitamin D and the metabolic status at children and teenagers with obesity. Questions of children’s dietology. 2013; 11(3):15–21].

43. Xue B, Greenberg AG, Kraemer FB, Zemel MB. Mechanism of intracellular calcium ([Ca2+]i) inhibition of lipolysis in human adipocytes. FASEB J. 2001;15(13):2527–2529.

44. Narvaez CJ, Matthews D, Broun E, Chan M, Welsh J. Lean phenotype and resistance to diet-induced obesity in vitamin D receptor knockout mice correlates with induction of uncoupling protein-1 in white adipose tissue. Endocrinology. 2009;150 (2):651–661.

45. de Paula FJ, Dick-de-Paula I, Bornstein S, Rostama B, Le P, Lotinun S et al. VDR haploinsufficiency impacts body composition and skeletal acquisition in a gender-specific manner. Calcif Tissue Int. 2011;89(3):179–191.

46. Cheng SP, Doherty GM, Chang YC, Liu CL. Leptin: the link between overweight and primary hyperparathyroidism? Med Hypotheses. 2011;76(1):94–96.

47. Rorsman P, Renstrom E. Insulin granule dynamics in pancreatic beta cells. Diabetologia. 2003;46(8):1029–1045.

48. Velasco M, Larqué C, Gutiérrez-Reyes G, Arredondo R, Sanchez-Soto C, Hiriart M. Metabolic syndrome induces changes in KATP-channels and calcium currents in pancreatic β-cells. Islets. 2012;4(4):302–311.

49. 9 . M a r c i n k o w s k i W, Z h a n g G , S m o g o r z e w s k i M , Massry SG. Elevation of (Ca2+)i of renal proximal tubule cells and downregulation of MRNA of PTH-PTHrP, V1a and AT1 receptors in kidneys of diabetic rats. Kidney Int. 1997;51(6):1950–1955.

50. Becerra-Tomás N, Estruch R, Bulló M, Casas R, DíazLópez A, Basora J et al. Increased serum calcium levels and risk of type 2 diabetes in individuals at high cardiovascular risk. Diabetes Care. 2014;37(11):3084–91. doi: 10.2337/dc14–0898.

51. Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61:91–104. doi: 10.1146/annurev.med.051308.111339.

52. Lourenço BH, Qi L, Willett WS, Cardoso MA. FTO genotype, vitamin D status, and weight gain during childhood ACTION Study Team. Diabetes. 2014;63(2):808–814. doi: 10.2337/db13–1290.

53. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease? J Am Soc Nephrol. 2004;15(11):2775–2791.

54. 4 . v a n E t t e n E , M a t h i e u C . I m m u n o r e g u l a t i o n b y 1,25-dihydroxyvitamin D-3: Basic concepts. J Steroid Biochem Mol Biol. 2005;97(1–2):93–101.

55. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770–1773.

56. Baker RG, Hayden MS, Ghosh S. NF-kappa B, inflammation, and metabolic disease. Cell Metab. 2011;13(1):11–22.

57. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile-1,25-Dihydroxyvitamin D-works as anti-inflammatory. Diabetes Res. Clin. Pract. 2007;77(1):47–57.

58. Chagas CE, Borges MS, Martini LA, Rogero MM. Focus on vitamin D, inflammation and type 2 diabetes review. Nutrients. 2012;4(1):52–67. doi: 10.3390/nu4010052.

59. Smotkin-Tangorra M, Purushothaman R, Gupta A, Nejati G, Anhalt H, Ten S. Prevalence of vitamin D insufficiency in obese children and adolescents. J Pediatr Endocrinol Metab. 2007;20 (7):817–823.

60. Kardas F, Kendirci M, Kurtoglu S. Cardiometabolic risk factors related to vitamin d and adiponectin in obese children and adolescents. Int J Endocrinol. 2013;2013:503270. doi: 10.1155/2013/503270.

61. Vimaleswaran KS, Cavadino A, Berry DJ, LifeLines Cohort Study investigators, Jorde R, Dieffenbach AK, Lu C et al. Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study, Lancet Diabetes Endocrinol. 2014;2(9):719–729. doi: 10.1016/S2213–8587 (14)70113–5.

62. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med. 2010;152(5):315–323. doi: 10.7326/0003–4819–152–5-201003020–00010.

63. Afzal S, Nordestgaard BG. Low vitamin D and hypertension: a causal association? Lancet Diabetes Endocrinol. 2014;2(9):682– 684. doi:10.1016/S2213–8587(14)70119–6 .

64. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochemistry. 2003;88(2):327–331.

65. Дудинская Е. Н., Ткачёва О. Н. Роль витамина D в развитии артериальной гипертензии. Кардиоваскулярная терапия и профилактика. 2012;11(3):77–81. [Dudinskaya E. N., Tkachyova O. N. Role of vitamin D in development of arterial hypertension. Cardiovascular therapy and prevention. 2012;11(3):77–81. In Russian].

66. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxy Vitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clinical Investigation. 2002;110 (2):229–238. doi:10.1172/JCI200215219.

67. Chen SC, Law CS, Grigsby CL, Olsen K, Gardner DG. A role for the cell cycle phosphatase Cdc25a in vitamin D-dependent inhibition of adult rat vascular smooth muscle cell proliferation. J Steroid Biochem Mol Biol. 2011;122(5):326–332.

68. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005;288(1):125–132.

69. Williams DM, Fraser A, Lawlor DA. Associations of vitamin D, parathyroid hormone and calcium with cardiovascular risk factors in US adolescents. Heart. 2011;97(4):315–320. doi: 10.1136/hrt.2010.203224.

70. Foltyn VN, Bendikov I, De Miranda J, Panizzutti R, Dumin E, Shleper M et al. Serine racemase modulates intracellular D-serine levels through an alpha, beta-elimination activity. J Biol Chem. 2005;280(3):1754–1763.

71. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2006;17(12):3382–3393.

72. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting Vitamin D receptor-mediated sequestration of NF-kB signaling. J. Am. Soc. Nephrol. 2008;19(9):1741–1752.

73. Damasiewicz MJ, Magliano DJ, Daly RM, Gagnon C, Lu ZX, Sikaris KA et al. Serum 25-hydroxyvitamin D deficiency and the 5-year incidence of CKD. Am. J. Kidney Diseases. 2013;62 (1):58–66. doi: 10.1053/j.ajkd.2013.03.010.

74. Hur E, Garip A, Camyar A, Ilgun S, Ozisik M, Tuna S et al. The effects of vitamin d on gentamicin-induced acute kidney injury in experimental rat model. Int. J. Endocrinol. 2013;2013:313–528. doi: 10.1155/2013/313528.

75. de Boer IH, Sachs MC, Chonchol M, Himmelfarb J, Hoofnagle AN, Ix JH et al. Estimated GFR and circulating 24,25-dihydroxyvitamin D3 concentration: a participant-level analysis of 5 cohort studies and clinical trial. Am. J. Kidney Dis. 2014;64(2):187–197. doi: 10.1053/j.ajkd.2014.02.015.

76. Смирнова Н. Н., Куприенко Н. Б. Нефропатия ожирения в педиатрии. Нефрология. 2013;6:37–45. [Smirnova NN, Kupriyenko NB. Оbesity-related nephropathy in pediatrics. Nephrology. 2013;6:37–45. In Russian].


Для цитирования:


Куприенко Н.Б., Смирнова Н.Н. ВИТАМИН D, ОЖИРЕНИЕ И РИСК КАРДИОРЕНАЛЬНЫХ НАРУШЕНИЙ У ДЕТЕЙ. Артериальная гипертензия. 2015;21(1):48-58. https://doi.org/10.18705/1607-419X-2015-21-1-48-58

For citation:


Kuprienko N.B., Smirnova N.N. VITAMIN D, OBESITY AND CARDIORENAL RISK IN CHILDREN. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2015;21(1):48-58. (In Russ.) https://doi.org/10.18705/1607-419X-2015-21-1-48-58

Просмотров: 423


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)